- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02140554
A Study Evaluating the Safety and Efficacy of bb1111 in Severe Sickle Cell Disease
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
California
-
Oakland, California, United States
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Maryland
-
Bethesda, Maryland, United States
-
-
New Jersey
-
Hackensack, New Jersey, United States
-
-
New York
-
Hyde Park, New York, United States
-
New York, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be ≥12 and ≤50 of age at time of consent.
- Diagnosis of sickle cell disease (SCD), with either βS/βS or βS/β0 or βS/β+ genotype.
Have severe SCD. i.e., in the setting of appropriate supportive care measures for SCD (e.g.,pain management plan) have experienced at least 4 severe VOEs in the 24 months prior to informed consent.
For the purposes of this study, a severe VOE is defined as an event with no medically determined cause other than a vaso-occlusion, requiring a ≥ 24-hour hospital or Emergency Room (ER) observation unit visit or at least 2 visits to a day unit or ER over 72 hours with both visits requiring intravenous treatment. Exception: priapism does not require hospital admission but does require a medical facility visit; 4 priapism episodes that require a visit to a medical facility (without inpatient admission) are sufficient to meet criterion.
- Karnofsky performance status of ≥ 60 (≥16 years of age) or a Lansky performance status of ≥60 (<16 years of age).
- Have either experienced hydroxyurea (HU) failure at any point in the past or must have intolerance to HU (defined as patient being unable to continue to take HU per PI judgement).
- Have been treated and followed for at least the past 24 months prior to Informed Consent in medical center(s) that maintained detailed records on SCD history.
Exclusion Criteria:
- Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV).
- Clinically significant and active bacterial, viral, fungal, or parasitic infection.
- Inadequate bone marrow function, as defined by an absolute neutrophil count of < 1000/µL (< 500/µL for subjects on HU treatment) or a platelet count < 100,000/µL.
- Any history of severe cerebral vasculopathy: defined by overt or hemorrhagic stroke; abnormal transcranial Doppler [≥200 cm/sec] needing chronic transfusion; or occlusion or stenosis in the polygon of Willis; or presence of Moyamoya disease. Subjects with radiologic evidence of silent infarction in the absence of any of the above criteria would still be eligible
Advanced liver disease, defined as:
- Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value >3× the upper limit of normal (ULN), or
- Baseline prothrombin time or partial thromboplastin time >1.5× ULN, suspected of arising from liver disease, or
- Magnetic Resonance Imaging (MRI) of the liver demonstrating clear evidence of cirrhosis, or
- MRI findings suggestive of active hepatitis, significant fibrosis, inconclusive evidence of cirrhosis, or liver iron concentration ≥15 mg/g require follow-up liver biopsy in subjects ≥18 years of age. In subjects <18 years of age, these MRI findings are exclusionary, unless in the opinion of the Investigator, a liver biopsy could provide additional data to confirm eligibility and would be safe to perform. If a liver biopsy is performed based on MRI findings, any evidence of cirrhosis, bridging fibrosis, or significant active hepatitis will be exclusionary.
- Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients.
- Any prior or current malignancy or immunodeficiency disorder, except previously treated, non-life threatening, cured tumors such as squamous cell carcinoma of the skin.
- Prior receipt of an allogeneic transplant.
- Immediate family member with a known or suspected Familial Cancer Syndrome.
- Diagnosis of significant psychiatric disorder of the subject that, in the Investigator's judgment, could seriously impede the ability to participate in the study.
- Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile subjects.
- Participation in another clinical study with an investigational drug within 30 days of Screening.
- Prior receipt of gene therapy.
- Patients needing curative anticoagulation therapy during the period of conditioning through platelet engraftment (patients on prophylactic doses of anticoagulants are eligible).
- Unable to receive RBC transfusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene. *No Longer Recruiting |
bb1111 is administered by IV infusion following myeloablative conditioning with busulfan.
Other Names:
|
Experimental: Group B
Group B1: Subjects will have rescue cells collected by bone marrow harvest, and will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene. *No Longer Recruiting Group B2: Plerixafor mobilization and apheresis will be used for collection of rescue cells and exploratory manufacturing development. Subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by bone marrow harvest transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene. *No Longer Recruiting |
bb1111 is administered by IV infusion following myeloablative conditioning with busulfan.
Other Names:
|
Experimental: Group C
Plerixafor mobilization and apheresis will be used for collection of rescue cells, and subjects will receive treatment of bb1111 manufactured with autologous CD34+ hematopoietic stem cells (HSCs) collected by plerixafor mobilization and apheresis transduced with BB305 lentiviral vector encoding the human beta-A-T87Q globin gene. *No Longer Recruiting |
bb1111 is administered by IV infusion following myeloablative conditioning with busulfan.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VOE-CR
Time Frame: 6-18 months post-transplant
|
Proportion of subjects achieving complete resolution of VOEs between 6 months and 18 months after drug product infusion
|
6-18 months post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sVOE-CR
Time Frame: 6-18 months post-transplant
|
Proportion of subjects achieving complete resolution of severe vaso-occlusive events, between 6 months and 18 months after drug product infusion
|
6-18 months post-transplant
|
sVOE-CR24
Time Frame: 6-24 months post-transplant
|
Proportion of subjects achieving complete resolution of severe VOEs between 6 months and 24 months after drug product infusion
|
6-24 months post-transplant
|
Proportion of Subjects achieving Globin Response
Time Frame: 6-24 months post-transplant
|
Globin Response, defined as meeting the following criteria for a continuous period of at least 6 months after drug product infusion:
|
6-24 months post-transplant
|
Change in the annualized number of vaso-occlusive events (VOEs) in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change in the annualized number of severe VOEs in the 24 months after drug product infusion as compared to the 24 months prior to informed consent
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
VOE-CR24
Time Frame: 6-24 months post-transplant
|
Proportion of subject achieving complete resolution of VOEs between 6 months and 24 months after drug product infusion
|
6-24 months post-transplant
|
sVOE-75
Time Frame: Through Month 24 post-transplant
|
Proportion of subjects achieving a 75% reduction in annualized severe VOEs in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent
|
Through Month 24 post-transplant
|
Proportion of subjects who meet the definition of Globin Response at Month 24
Time Frame: Month 24 post-transplant
|
Month 24 post-transplant
|
|
Duration of Globin Response
Time Frame: 6-24 months post-transplant
|
6-24 months post-transplant
|
|
Weighted average non-transfused total Hb
Time Frame: Month 6, 12, 18, and 24 post-transplant
|
Month 6, 12, 18, and 24 post-transplant
|
|
Weighted average HbS percentage of non-transfused total Hb
Time Frame: Month 6, 12, 18, and 24 post-transplant
|
Month 6, 12, 18, and 24 post-transplant
|
|
Weighted average HbAT87Q percentage of non-transfused total Hb
Time Frame: Month 6, 12, 18, and 24 post-transplant
|
Month 6, 12, 18, and 24 post-transplant
|
|
Weighted average HbS percentage of non-transfused total Hb ≤ 70%, ≤ 60%, ≤ 50%
Time Frame: Month 6, 12, 18, and 24 post-transplant
|
Month 6, 12, 18, and 24 post-transplant
|
|
Weighted average non-HbS percentage of non-transfused total Hb
Time Frame: Month 6, 12, 18, and 24 post-transplant
|
Month 6, 12, 18, and 24 post-transplant
|
|
Average and median of non-transfused total Hb over time
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Average and median of HbS percentage of non-transfused total Hb over time
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Average and median of HbAT87Q percentage of non-transfused total Hb over time
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Average and median of non-HbS percentage of non-transfused total Hb over time
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in hemolysis markers
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in markers of iron stores
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in annualized frequency and volume of packed red blood cell (pRBC) transfusions
Time Frame: 6 - 24 months post-transplant
|
6 - 24 months post-transplant
|
|
Change from baseline in markers of stress erythropoiesis
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in renal function as measured by eGFR
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in cardiac-pulmonary function via echocardiogram (tricuspid regurgitant jet velocity [TRJV], LVEF)
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in cardiac-pulmonary function via pulmonary function tests
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in meters walked during 6-minute walk test
Time Frame: Through Month 24 post-transplant
|
Through Month 24 post-transplant
|
|
Change from baseline in annualized VOE-related hospital admissions
Time Frame: From post-transplant hospital discharge to Month 24 post-transplant
|
From post-transplant hospital discharge to Month 24 post-transplant
|
|
Change from baseline in annualized total days hospitalized
Time Frame: From post-transplant hospital discharge to Month 24 post-transplant
|
From post-transplant hospital discharge to Month 24 post-transplant
|
|
Change from baseline in patient-reported quality of life, as measured by Patient Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Month 3, 6, 12, 18, and 24 post-transplant
|
Month 3, 6, 12, 18, and 24 post-transplant
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Anjulika Chawla, MD, FAAP, bluebird bio, Inc.
Publications and helpful links
General Publications
- Del Pozo Martin Y. 47th Annual Meeting of the EBMT. Lancet Haematol. 2021 May;8(5):e317-e318. doi: 10.1016/S2352-3026(21)00104-6. Epub 2021 Mar 31. No abstract available.
- Del Pozo Martin Y. 2021 ASH annual meeting. Lancet Haematol. 2022 Feb;9(2):e92-e93. doi: 10.1016/S2352-3026(21)00384-7. Epub 2021 Dec 16. No abstract available.
- Kanter J, Thompson AA, Pierciey FJ Jr, Hsieh M, Uchida N, Leboulch P, Schmidt M, Bonner M, Guo R, Miller A, Ribeil JA, Davidson D, Asmal M, Walters MC, Tisdale JF. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023 Jan;98(1):11-22. doi: 10.1002/ajh.26741. Epub 2022 Oct 10.
- Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, Aygun B, Kasow KA, Pierciey FJ Jr, Bonner M, Miller A, Zhang X, Lynch J, Kim D, Ribeil JA, Asmal M, Goyal S, Thompson AA, Tisdale JF. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med. 2022 Feb 17;386(7):617-628. doi: 10.1056/NEJMoa2117175. Epub 2021 Dec 12.
- Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021 Sep 16;138(11):942-947. doi: 10.1182/blood.2021011488.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HGB-206
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingSickle Cell Disease | Sickle Cell SC Disease | Sickle Cell-SS Disease | Sickle Cell RetinopathyNetherlands
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
Clinical Trials on bb1111
-
bluebird bioRecruitingSickle Cell DiseaseUnited States